NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 224.95M |
| Revenue (ttm) | 83,000 |
| Net Income (ttm) | -11.90M |
| Shares Out | 18.75M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,742 |
| Open | 14.00 |
| Previous Close | 12.11 |
| Day's Range | 10.88 - 14.00 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NTHI
NeOnc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases in the United States. The company offers products, including NEO100, a purified form of perillyl acid administered intranasally to treat brain cancer patients, and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NeOnc Technologies Holdings, Inc. was formerly known as NAS-ONC, Inc. and changed its name to NeOnc T... [Read more]
Financial Performance
In 2024, NTHI's revenue was $83,000, an increase of 17.79% compared to the previous year's $70,462. Losses were -$11.90 million, -20.26% less than in 2023.
Financial StatementsNews
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic...
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
Delshad adds broad management and financial expertise to the NeOnc team Delshad adds broad management and financial expertise to the NeOnc team
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience an...
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings
Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on...
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook NeOnc's Novel Intranasal...
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
WESTLAKE VILLAGE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has begun patient enrollment for the Phase 2 clinical tr...
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
WESTLAKE VILLAGE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, received FDA approval to expand its ongoing NEO100-01™ Ph...
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
WESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the o...
NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award
Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases Clinical-Stage Biopharmaceutical Co...
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award SoCal-b...
U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week
Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings - Boundless Bio, U-BX Technology, Alta Global, and IB Acquisition, respectively. Three IPOs submitted initial...
U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline
One small Asian issuer went public in the US this past week, ahead of the Christmas holiday. Japanese e-commerce firm Linkage Global priced at the low end to raise $6 million at an $86 million market ...
Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline
Neonc Technologies Holdings, Inc. has filed for a $50 million IPO to develop new drug treatment candidates for brain cancer, although the final figure may differ. The firm's lead candidate, NEO100, is...